Cytokinetics, (CYTK) Reaches $8.70 After 7.00% Down Move; Zagg Delaware (ZAGG) Shorts Down By 4.56%

February 15, 2018 - By Michael Collier

The stock of Cytokinetics, Incorporated (NASDAQ:CYTK) is a huge mover today! The stock decreased 3.33% or $0.3 during the last trading session, reaching $8.7. About 137,379 shares traded. Cytokinetics, Incorporated (NASDAQ:CYTK) has risen 88.33% since February 15, 2017 and is uptrending. It has outperformed by 71.63% the S&P500.The move comes after 8 months negative chart setup for the $468.80M company. It was reported on Feb, 15 by Barchart.com. We have $8.09 PT which if reached, will make NASDAQ:CYTK worth $32.82M less.

Zagg Delaware (NASDAQ:ZAGG) had a decrease of 4.56% in short interest. ZAGG’s SI was 1.59M shares in February as released by FINRA. Its down 4.56% from 1.66 million shares previously. With 1.13M avg volume, 1 days are for Zagg Delaware (NASDAQ:ZAGG)’s short sellers to cover ZAGG’s short positions. The SI to Zagg Delaware’s float is 5.87%. The stock increased 0.77% or $0.125 during the last trading session, reaching $16.325. About 157,479 shares traded. ZAGG Inc (NASDAQ:ZAGG) has risen 54.72% since February 15, 2017 and is uptrending. It has outperformed by 38.02% the S&P500.

ZAGG Inc, together with its subsidiaries, designs, makes, and distributes mobile tech accessories for smartphones and tablets in the United States, Europe, and internationally. The company has market cap of $456.70 million. The firm operates through ZAGG and mophie divisions. It has a 161.63 P/E ratio. It offers screen protection products; battery cases and power management products for tablets, smartphones, MP3 players, cameras, and other electronic mobile devices; device specific keyboards and device agnostic keyboards; earbuds, headphones, Bluetooth speakers, and cables under the ZAGG, InvisibleShield, IFROGZ, and mophie brands.

Among 7 analysts covering ZAGG (NASDAQ:ZAGG), 4 have Buy rating, 0 Sell and 3 Hold. Therefore 57% are positive. ZAGG had 18 analyst reports since August 5, 2015 according to SRatingsIntel. Northland Capital maintained ZAGG Inc (NASDAQ:ZAGG) on Monday, September 11 with “Buy” rating. The firm has “Buy” rating by Wunderlich given on Friday, June 9. On Friday, December 1 the stock rating was maintained by Northland Capital with “Buy”. As per Tuesday, October 17, the company rating was maintained by Roth Capital. The rating was maintained by Craig Hallum with “Buy” on Thursday, October 19. The firm has “Buy” rating given on Tuesday, July 25 by Northland Capital. The firm has “Hold” rating by Roth Capital given on Wednesday, August 2. On Thursday, June 15 the stock rating was maintained by Roth Capital with “Hold”. TH Capital maintained ZAGG Inc (NASDAQ:ZAGG) rating on Wednesday, August 5. TH Capital has “Neutral” rating and $8 target. The stock of ZAGG Inc (NASDAQ:ZAGG) has “Buy” rating given on Wednesday, November 2 by Wunderlich.

Investors sentiment increased to 1.27 in Q3 2017. Its up 0.13, from 1.14 in 2017Q2. It is positive, as 13 investors sold ZAGG Inc shares while 35 reduced holdings. 30 funds opened positions while 31 raised stakes. 21.90 million shares or 0.15% more from 21.87 million shares in 2017Q2 were reported. Fmr Llc holds 0% or 114,820 shares in its portfolio. Jpmorgan Chase And invested 0% in ZAGG Inc (NASDAQ:ZAGG). Dimensional Fund Advisors Lp holds 0.02% or 2.23M shares. Citigroup holds 0% of its portfolio in ZAGG Inc (NASDAQ:ZAGG) for 7,984 shares. Barclays Public Ltd has 1,626 shares. Ny State Common Retirement Fund owns 26,900 shares. California Public Employees Retirement System owns 125,699 shares. Credit Suisse Ag owns 17,941 shares. Jane Street Grp Inc Ltd Co reported 22,789 shares. Reliance Of Delaware has 0.02% invested in ZAGG Inc (NASDAQ:ZAGG) for 10,263 shares. Cornercap Invest Counsel Inc reported 65,255 shares. Goldman Sachs Grp Inc holds 0% or 31,934 shares in its portfolio. 31,770 are owned by Columbia Pacific Advsr Llc. Granite Point Cap Management Lp holds 0.36% or 108,500 shares. Wells Fargo And Mn, a California-based fund reported 42,705 shares.

Since August 29, 2017, it had 0 buys, and 11 insider sales for $2.66 million activity. On Thursday, August 31 Morgan Bradley Paul sold $1.77M worth of Cytokinetics, Incorporated (NASDAQ:CYTK) or 118,330 shares. On Monday, October 2 GAGE L PATRICK sold $72,944 worth of Cytokinetics, Incorporated (NASDAQ:CYTK) or 5,000 shares. COSTA SANTO J sold $70,000 worth of stock. 10,131 shares were sold by McDowell Caryn Gordon, worth $147,864 on Wednesday, September 6. Shares for $72,957 were sold by Blum Robert I on Monday, October 2.

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company has market cap of $468.80 million. The firm is developing small molecule drug candidates primarily engineered to increase muscle function and contractility. It currently has negative earnings. The Company’s lead drug candidate is Tirasemtiv, a fast skeletal troponin activator, which is in Phase III clinical trial in patients with amyotrophic lateral sclerosis.

Among 12 analysts covering Cytokinetics (NASDAQ:CYTK), 11 have Buy rating, 0 Sell and 1 Hold. Therefore 92% are positive. Cytokinetics has $2600 highest and $13.0 lowest target. $19.67’s average target is 126.09% above currents $8.7 stock price. Cytokinetics had 22 analyst reports since July 24, 2015 according to SRatingsIntel. The firm has “Buy” rating by Piper Jaffray given on Tuesday, November 21. The stock of Cytokinetics, Incorporated (NASDAQ:CYTK) earned “Buy” rating by Piper Jaffray on Tuesday, October 10. Needham maintained Cytokinetics, Incorporated (NASDAQ:CYTK) on Wednesday, July 27 with “Buy” rating. TH Capital maintained Cytokinetics, Incorporated (NASDAQ:CYTK) on Monday, November 9 with “Buy” rating. The stock of Cytokinetics, Incorporated (NASDAQ:CYTK) has “Buy” rating given on Monday, November 9 by Roth Capital. Needham upgraded Cytokinetics, Incorporated (NASDAQ:CYTK) rating on Monday, February 6. Needham has “Strong Buy” rating and $22 target. Morgan Stanley maintained the stock with “Buy” rating in Wednesday, November 22 report. The stock has “Buy” rating by H.C. Wainwright on Friday, October 27. The stock has “Market Outperform” rating by JMP Securities on Wednesday, March 9. The rating was maintained by H.C. Wainwright on Thursday, August 3 with “Buy”.

Investors sentiment decreased to 1.39 in 2017 Q3. Its down 1.55, from 2.94 in 2017Q2. It dropped, as 16 investors sold Cytokinetics, Incorporated shares while 30 reduced holdings. 21 funds opened positions while 43 raised stakes. 39.12 million shares or 3.53% more from 37.79 million shares in 2017Q2 were reported. Federated Invsts Pa reported 0% in Cytokinetics, Incorporated (NASDAQ:CYTK). Mason Street Advisors Ltd Liability Corp holds 12,776 shares. Alliancebernstein Ltd Partnership has 0% invested in Cytokinetics, Incorporated (NASDAQ:CYTK). Prelude Mgmt Limited reported 35,804 shares or 0.05% of all its holdings. 89,116 are held by Clarivest Asset Management Ltd Liability Corp. Pinebridge Invests Limited Partnership holds 0% or 6,261 shares in its portfolio. Manufacturers Life The, Ontario – Canada-based fund reported 32,615 shares. Arizona State Retirement Systems accumulated 0% or 26,200 shares. California State Teachers Retirement Sys holds 0% in Cytokinetics, Incorporated (NASDAQ:CYTK) or 66,456 shares. Acadian Asset Management Ltd Liability Co has invested 0.03% in Cytokinetics, Incorporated (NASDAQ:CYTK). State Of Wisconsin Board invested in 30,000 shares. Granite Inv Prtnrs Ltd Com holds 0.04% or 39,732 shares in its portfolio. Wade G W invested 0.04% in Cytokinetics, Incorporated (NASDAQ:CYTK). Swiss Natl Bank, a Switzerland-based fund reported 65,200 shares. Royal Fincl Bank Of Canada holds 0% or 17,181 shares in its portfolio.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.